D
Denis Caillot
Researcher at French Institute of Health and Medical Research
Publications - 342
Citations - 24938
Denis Caillot is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Transplantation & Multiple myeloma. The author has an hindex of 69, co-authored 320 publications receiving 22247 citations. Previous affiliations of Denis Caillot include University of Limoges & Institut Gustave Roussy.
Papers
More filters
Journal ArticleDOI
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Raoul Herbrecht,David W. Denning,David W. Denning,Thomas F. Patterson,John E. Bennett,Reginald Greene,Reginald Greene,J. W. Oestmann,Winfried V. Kern,Winfried V. Kern,Winfried V. Kern,Kieren A. Marr,Patricia Ribaud,Olivier Lortholary,Richard J. Sylvester,Robert H. Rubin,John R. Wingard,Paul Stark,Christine Durand,Denis Caillot,Eckhard Thiel,Pranatharthi H. Chandrasekar,Michael R. Hodges,Haran T. Schlamm,Peter F. Troke,Ben E. De Pauw +25 more
TL;DR: In patients with invasive aspergillosis,Initial therapy with voriconazole led to better responses and improved survival and resulted in fewer severe side effects than the standard approach of initial therapy with amphotericin B.
Journal ArticleDOI
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal,Valérie Lauwers-Cances,Gerald Marit,Denis Caillot,Philippe Moreau,Thierry Facon,Anne-Marie Stoppa,Cyrille Hulin,Lofti Benboubker,Laurent Garderet,Olivier Decaux,Serge Leyvraz,Marie-Christiane Vekemans,Laurent Voillat,Mauricette Michallet,Brigitte Pegourie,Charles Dumontet,Murielle Roussel,Xavier Leleu,Claire Mathiot,Catherine Payen,Hervé Avet-Loiseau,Jean-Luc Harousseau +22 more
TL;DR: Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma.
Journal ArticleDOI
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Michel Attal,Jean-Luc Harousseau,Thierry Facon,François Guilhot,Chantal Doyen,Jean-Gabriel Fuzibet,Mathieu Monconduit,Cyrille Hulin,Denis Caillot,Reda Bouabdallah,Laurent Voillat,Jean-Jacques Sotto,Bernard Grosbois,Régis Bataille +13 more
TL;DR: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Journal ArticleDOI
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau,Michel Attal,Philippe Moreau,Catherine Charbonnel,Frédéric Garban,Cyrille Hulin,Serge Leyvraz,Mauricette Michallet,Ibrahim Yakoub-Agha,Laurent Garderet,Gerald Marit,Lucienne Michaux,Laurent Voillat,Marc Renaud,Bernard Grosbois,Gaelle Guillerm,Lotfi Benboubker,Mathieu Monconduit,Catherine Thieblemont,Philippe Casassus,Denis Caillot,Anne-Marie Stoppa,Jean-Jacques Sotto,Marc Wetterwald,Charles Dumontet,Jean-Gabriel Fuzibet,Isabelle Azais,Véronique Dorvaux,Marc Zandecki,Régis Bataille,Stephane Minvielle,Jean-Luc Harousseau,Thierry Facon,Claire Mathiot +33 more
TL;DR: In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal,Valérie Lauwers-Cances,Cyrille Hulin,Xavier Leleu,Denis Caillot,Martine Escoffre,Bertrand Arnulf,Margaret Macro,Karim Belhadj,Laurent Garderet,Murielle Roussel,Catherine Payen,Claire Mathiot,Jean Paul Fermand,Nathalie Meuleman,Sandrine Rollet,Michelle E. Maglio,Andrea A. Zeytoonjian,Edie Weller,Nikhil C. Munshi,Kenneth C. Anderson,Paul G. Richardson,Thierry Facon,Hervé Avet-Loiseau,Jean-Luc Harousseau,Philippe Moreau +25 more
TL;DR: Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression‐free survival than RVD Therapy alone, but overall survival did not differ significantly between the two approaches.